m.yildiz

TL2 · Breda

Contributes reviews on supplier material. Based in Breda.

Joined 4 April 2025 · last posted 22h

84 posts, newest first. Showing up to 150.

CJC-1295 with and without DAC: what the modification does Replied, post #124 · Compounds › Secretagogues & GH axis · 27 Jul 2026 · 10 likes Building on post #121 rather than restating it. Small methodological point on CJC-1295: repeating a measurement is cheap and resolves most of what is being argued about…
Deletion sequences: expected mass shifts by residue — the long version Replied, post #25 · Analytics › Impurities & related substances · 27 Jul 2026 · 0 likes Incomplete deprotection: mass higher by the protecting group mass. Usually markedly later eluting. A synthesis artifact from incomplete removal of protecting groups.
Coming back to: Preparing for an appointment: one page, three questions Replied, post #41 · Clinical › Prescriber conversations · 24 Jul 2026 · 26 likes Everything in post #37 holds. The case it does not cover is the one I have. A question phrased as "what would you want to see before considering X" is answerable and is…
Reading order for a first week here, and what to skip until later — what changed since Replied, post #73 · Start Here › Welcome · 23 Jul 2026 · 0 likes The compound and evidence pages are updated regularly and they are worth reading when you are new. They answer the meta questions like "do we have data on this" and…
Revisiting: Protein density versus volume when you cannot eat much Replied, post #89 · Nutrition & Training › Protein & intake · 21 Jul 2026 · 26 likes Answering the question post #87 raises rather than the one it answers. Renal considerations around higher protein intake apply to people with existing renal impairment…
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #32 · Compounds › Semaglutide · 18 Jul 2026 · 0 likes Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be…
Which categories are strict and which are relaxed, honestly Replied, post #21 · Start Here › Welcome · 17 Jul 2026 · 0 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Seven-day rolling means and why weekly readings mislead Replied, post #43 · Outcomes › Progress reports · 16 Jul 2026 · 25 likes Worth separating two things that post #39 runs together. Menstrual cycle: for people who menstruate, weight can shift by several pounds across the cycle due to fluid…
Follow-up: How compounding permissions changed when supply normalised Replied, post #9 · Sourcing › Regulatory · 11 Jul 2026 · 8 likes Post #5 put the caveat in the right place and I want to underline it. A compound in a compounding pathway in one country and unavailable in another is a common…
A site rotation scheme that is easy enough to actually follow Replied, post #110 · Practice › Administration · 9 Jul 2026 · 0 likes The honest answer on site rotation scheme is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.…
Primary endpoint hierarchies and why order matters — one year on Replied, post #30 · Evidence › Trials · 29 Jun 2026 · 9 likes Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive on at least one by random chance increases. This is why…
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #21 · Practice › Dosing & titration · 27 Jun 2026 · 24 likes Adding the measurement that post #18 says would settle it. If you are stepping up mainly because the schedule says so rather than because the current dose has stopped…
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #46 · Compounds › Secretagogues & GH axis · 23 Jun 2026 · 3 likes On post #44 — agreed on the reasoning, with one qualification. Timing arguments in this family generally rest on the assumption that endogenous release is suppressed by…
Why we ask for units every single time, with three examples of what goes wrong Replied, post #59 · Start Here › How to Ask · 21 Jun 2026 · 7 likes Coming back to post #57, because the follow-up matters more than the original answer. A photograph of a vial is rarely useful and a photograph of a document usually is.…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #11 · Analytics › Impurities & related substances · 19 Jun 2026 · 5 likes An impurity profile that changes between lots is more informative than the total. A stable profile suggests a controlled process; a shifting one suggests something is…
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #79 · Data & Tools › Datasets · 12 Jun 2026 · 17 likes Small correction to my own earlier position on community side-effect dataset. I had the units the wrong way round, which changes the conclusion by an order of magnitude…
What to include when your question involves a chromatogram — one year on Replied, post #31 · Start Here › How to Ask · 9 Jun 2026 · 8 likes Good question, well framed, and I would like to see it answered properly.
Second pass at: Sleep apnoea improving and the equipment implications Replied, post #51 · Wellbeing › Sleep · 5 Jun 2026 · 26 likes Everything in post #47 holds. The case it does not cover is the one I have. Where sleep worsened at the same time as an escalation and improved afterwards, that…
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #85 · Outcomes › Body composition · 29 May 2026 · 17 likes Bone mineral density changes with substantial weight loss are measurable and slow, and are one of the better reasons to have a baseline scan.
What a certificate commits its issuer to — one year on Replied, post #76 · Analytics › COA interpretation · 27 May 2026 · 0 likes A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to sanity-check an integration and not enough to…
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #30 · Analytics › Method validation · 23 May 2026 · 18 likes I had written a reply contradicting post #27 and deleted it. Here is what survived. Practical answer on Specificity, since the theoretical one is upthread: do the…
Follow-up: Comparing two chromatograms from different laboratories, properly Replied, post #24 · Analytics › HPLC & UHPLC · 9 May 2026 · 0 likes I came in to disagree and I am leaving without a disagreement.
EU-wide position versus national implementation — what changed since Replied, post #25 · Regional › European Union · 1 May 2026 · 10 likes Everything in post #21 holds. The case it does not cover is the one I have. Reporting rather than recommending, on eu-wide position versus national implementation. What…
Pregnancy and pregnancy planning: contraindication and washout Replied, post #123 · Clinical › Special populations · 25 Apr 2026 · 21 likes Pregnancy and planning: these compounds are not approved for use in pregnancy. Planning windows (how long to wait before attempting pregnancy) are not formally…
Follow-up: Reconciling a label claim with a content assay Replied, post #16 · Analytics › COA interpretation · 22 Apr 2026 · 0 likes No disagreement from me. Posting only so the question does not look ignored.
Follow-up: State-level differences that actually matter Replied, post #7 · Regional › North America · 3 Apr 2026 · 0 likes The bit of State-level differences that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the…
Five questions in one post gets you one answer — how to split them Replied, post #45 · Start Here › How to Ask · 2 Apr 2026 · 0 likes Picking up post #42: that is the part I would want checked first. Say what you want out of the answer. "I want to know whether to accept this delivery" and "I want to…
Amylin receptor signalling and satiety — what changed since Replied, post #53 · Pharmacology › Receptor biology · 30 Mar 2026 · 8 likes Answering the question post #52 raises rather than the one it answers. GIP receptor biology is genuinely contested. Both agonism and antagonism have been argued to…
Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #77 · Compounds › Cagrilintide & amylin analogues · 19 Mar 2026 · 2 likes Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's…
An ABAB design with a data table and honest limitations — a second dataset Replied, post #79 · Research Methods › N-of-1 designs · 19 Mar 2026 · 0 likes I would keep ABAB design and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why…
Revisiting: Absolute versus relative contraindications Replied, post #43 · Safety › Contraindications · 14 Mar 2026 · 0 likes Quietly grateful for the plain phrasing. Not every thread gets that.
Journal club: semaglutide in MASH, and surrogate endpoints Replied, post #10 · Evidence › Journal club · 7 Mar 2026 · 5 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
Reused chromatograms across lots: how to spot it — what changed since Replied, post #17 · Analytics › COA interpretation · 13 Feb 2026 · 6 likes I would rather this thread reach "we do not know" about Reused chromatograms across lots than reach a confident answer that nobody can support when asked.
Injection discomfort: needle gauge, volume, temperature, technique Replied, post #22 · Practice › Administration · 3 Feb 2026 · 6 likes That is the distinction I keep failing to hold on to. Written down now.
Promotion criteria, and the one that stops most nominations — the long version Replied, post #128 · Documentation › Doc review · 8 Jan 2026 · 0 likes Post #125 is right about the mechanism and I think understates the practical bit. The reason Promotion criteria is hard to answer is that the obvious measurement and…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #54 · Pharmacology › Pharmacokinetics · 7 Jan 2026 · 6 likes I had written a reply contradicting post #51 and deleted it. Here is what survived. Steady state is approached in roughly four to five half-lives. For a compound with a…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #66 · Compounds › Tirzepatide · 9 Dec 2025 · 18 likes Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted…
Second pass at: The topic list is dense — is that deliberate? Replied, post #9 · Meta › Site feedback · 28 Nov 2025 · 18 likes Post #6 put the caveat in the right place and I want to underline it. Since topic list keeps coming up, it should probably be a maintained page rather than a recurring…
Reading SURMOUNT-1 without the press release — one year on Replied, post #25 · Compounds › Tirzepatide · 27 Nov 2025 · 0 likes Answering the question post #23 raises rather than the one it answers. Storage and stability: published data on licensed tirzepatide formulations exists and is worth…
Revisiting: Aggregates and why a purity assay may miss them entirely Replied, post #12 · Analytics › Impurities & related substances · 15 Nov 2025 · 0 likes Truncation products are substantially lower in mass and usually well separated chromatographically, which makes them the easiest class to see and the least likely to be…
[2026 update] What steady state means for the decision to escalate Replied, post #55 · Practice › Dosing & titration · 10 Nov 2025 · 0 likes Taking post #53 at face value and following it one step further. A request rather than an answer: could whoever has the primary source for steady state post it? I have…
Coming back to: Why most self-reports here are not experiments, and that is fine Replied, post #16 · Research Methods › N-of-1 designs · 2 Nov 2025 · 6 likes Post #14 and I disagree about the size of the effect, not about the direction. Objective versus subjective measures: subjective measures (how you feel) are vulnerable…
New subcategory: rationale and scope Replied, post #39 · Meta › Announcements · 16 Oct 2025 · 0 likes Second this, and I would have said it less carefully.
Journal club: how we handle discontinuation in obesity trials — what changed since Replied, post #9 · Evidence › Journal club · 3 Oct 2025 · 6 likes I had written a reply contradicting post #7 and deleted it. Here is what survived. Where the group cannot agree, record the disagreement rather than resolving it by…
Sleep quality changes during weight loss — what changed since Replied, post #11 · Wellbeing › Sleep · 28 Sep 2025 · 0 likes The published data on sleep outcomes in this class is thinner than the volume of discussion, which is worth saying plainly. Same conclusion as the reply above, reached…
Which panel is worth repeating and which is worth ignoring Replied, post #122 · Clinical › Bloodwork · 27 Sep 2025 · 12 likes Post #118 describes the usual case. This is about the unusual one. A trend needs at least three points to be a trend. Two points are a line and a line through noise is…
Discussing something you have already been doing Replied, post #8 · Clinical › Prescriber conversations · 23 Sep 2025 · 3 likes Post #4 describes the usual case. This is about the unusual one. Prescription logistics: confirm whether it will be filled locally, requires mail order, or will be…
Payment method and the leverage it gives you, ranked Replied, post #59 · Sourcing › Payments · 23 Sep 2025 · 16 likes Payment method: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
What this community means by "a source", in practical terms Replied, post #99 · Start Here › Welcome · 4 Sep 2025 · 22 likes If you want a fast orientation, read three solved topics in the subcategory you care about. Solved means somebody said the answer worked, which is more signal than…
Coming back to: What published stability data actually covers, and what it does not Replied, post #117 · Practice › Storage & stability · 19 Aug 2025 · 1 like Published stability data actually covers has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done…
Cost per delivered dose, which is the number that matters Started this topic · Access › Pricing · 3 Aug 2025 · 3 likes Cost per delivered dose, which is the number that matters — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated,…
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #32 · Sourcing › Regulatory · 23 Jun 2025 · 10 likes Understood, and I withdraw the assumption I opened with.
Sodium, potassium and magnesium when intake drops Replied, post #22 · Nutrition & Training › Hydration & electrolytes · 19 Jun 2025 · 11 likes Potassium: similar to sodium; losing weight involves some potassium loss. Bananas, sweet potatoes, and other potassium-rich foods help. Severe depletion is rare but…
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #128 · Compounds › Semaglutide · 22 May 2025 · 12 likes Summarising the SELECT thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is…
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Replied, post #16 · Evidence › Journal club · 6 May 2025 · 0 likes Where I part company with post #13, and it is a narrow parting. Reading order that works for these sessions: registry entry, methods, baseline table, primary result,…
Journal club: indirect comparison between two programmes, defended and attacked — one… Replied, post #6 · Evidence › Journal club · 5 May 2025 · 12 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
Filing a first vendor report: a worked example Replied, post #6 · Sourcing › Vendor reports · 29 Apr 2025 · 0 likes Post #5 is the version of this I will quote in future. One addition. A difference inside method repeatability is not a disagreement. Saying so in your own report…
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #21 · Evidence › Journal club · 24 Apr 2025 · 25 likes The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping. I…
Counter-ion content and its effect on measured mass Replied, post #23 · Analytics › Mass spectrometry · 23 Apr 2025 · 12 likes Before the thread moves on from counter-ion content — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n…
The C-cell question: rodent findings and their human context Replied, post #10 · Compounds › Semaglutide · 23 Apr 2025 · 7 likes Post #6 and I disagree about the size of the effect, not about the direction. The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #122 · Evidence › Journal club · 22 Apr 2025 · 0 likes Confirming post #121 from a second method, which matters more than confirming it from a second person. Where I have landed on STEP 1, having got it wrong once in…
UK access routes, dated and sourced — a second dataset Replied, post #65 · Regional › UK & Ireland · 17 Apr 2025 · 5 likes Picking up post #62: that is the part I would want checked first. Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is…
A well-designed study with a badly written abstract Replied, post #21 · Evidence › Study critique · 12 Apr 2025 · 14 likes Post #18 is the version of this I will quote in future. One addition. Second-hand on well-designed study, so weight it accordingly — someone whose method I trust told…
Follow-up: Open-label extensions: what survives and what does not Replied, post #24 · Evidence › Trials · 2 Apr 2025 · 0 likes Building on post #23 rather than restating it. The most useful thing anyone has posted about Open-label extensions in this category was a table of what had been…
A supplier that answers analytical questions with restated claims Replied, post #34 · Sourcing › Red flags · 5 Mar 2025 · 0 likes This follows post #33 rather than contradicting it. Supplier: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the…
Pharmaceutical compounding rules, summarised from primary sources Replied, post #18 · Sourcing › Regulatory · 28 Feb 2025 · 14 likes Coming back to post #14, because the follow-up matters more than the original answer. Nobody has said the unglamorous part of pharmaceutical compounding rules yet, so:…
What changed in 2026, by region Replied, post #119 · Access › International · 3 Feb 2025 · 4 likes Post #116 is the version of this I will quote in future. One addition. Both are useful and they are different contributions. A first-hand account and a citation answer…
Scheduled maintenance and what will be unavailable Replied, post #13 · Meta › Announcements · 11 Jan 2025 · 2 likes Marking my uncertainty on scheduled maintenance explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it…
A promotion I argued against, and why I lost Replied, post #49 · Documentation › Doc review · 3 Jan 2025 · 4 likes Adding the measurement that post #48 says would settle it. Checked the promotion claim against the primary source this morning. It survives, with a narrower scope than…
Coming back to: Grapefruit: why this class is not the class that cares Replied, post #44 · Practice › Interactions · 2 Jan 2025 · 0 likes Worth separating two things that post #42 runs together. Anticoagulant questions come up regularly and are the clearest case for professional advice rather than…
The report format the maintainers ask for, and why each field is there — what changed… Replied, post #2 · Sourcing › Vendor reports · 23 Dec 2024 · 10 likes Photograph the vial and the label before opening. It costs ten seconds and it is what turns a report into something checkable. That matches what I was told, which is…
Body image changing more slowly than the body Replied, post #51 · Wellbeing › Mental health · 16 Dec 2024 · 22 likes This follows post #48 rather than contradicting it. Body image: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere…
[2026 update] Step therapy requirements and how to satisfy them Replied, post #54 · Access › Insurance & coverage · 4 Dec 2024 · 29 likes Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves…
Revisiting: Bug report: the reconstitution calculator and a rounding edge case Replied, post #6 · Data & Tools › Calculators · 28 Nov 2024 · 0 likes Post #3 answers the question as asked. The question underneath it is different. Storage lookup: which conditions (temperature, time) are you considering storing in, and…
Injection-site reactions: describing them precisely enough to be useful Replied, post #29 · Practice › Side effects · 27 Nov 2024 · 17 likes I read post #26 twice before replying, because I had assumed the opposite. What I would want before treating injection-site reactions as settled: the method, the…
Tracking semaglutide's approved indications across jurisdictions, dated — does this… Replied, post #31 · Compounds › Semaglutide · 18 Nov 2024 · 7 likes Worth separating two things that post #27 runs together. Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach…
EMA product information as a primary source — does this still hold? Replied, post #51 · Regional › European Union · 16 Nov 2024 · 2 likes Post #48 is right about the mechanism and I think understates the practical bit. An honest declaration on EMA product information: I have a prior here and it is strong…
Promotion criteria, and the one that stops most nominations Replied, post #98 · Documentation › Doc review · 29 Oct 2024 · 0 likes Filing a mild objection to the consensus on promotion criteria. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Micronutrient status when intake falls substantially — a second dataset Replied, post #3 · Clinical › Bloodwork · 5 Oct 2024 · 8 likes Repeat before acting is standard practice for an isolated abnormal result on most analytes, and it is standard for a reason.
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #59 · Sourcing › Independent verification · 15 Sep 2024 · 21 likes Verification records are dated because they expire in usefulness. A result from two years ago describes a lot from two years ago. The short version is the first…
Identical chromatograms across two different lots Replied, post #17 · Sourcing › Red flags · 22 Aug 2024 · 5 likes Worth separating identical chromatograms as a question about the compound from identical chromatograms as a question about the documentation. They get answered by…
Chronic kidney disease and the FLOW result Replied, post #30 · Clinical › Comorbidities · 20 Aug 2024 · 31 likes Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute…
Correlation in a self-tracked dataset: what it can support Replied, post #2 · Research Methods › Statistics · 19 Aug 2024 · 0 likes Picking up the opening post: that is the part I would want checked first. Posting my correlation numbers with the method attached so they can be discounted properly.…
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #10 · Evidence › Journal club · 4 Aug 2024 · 0 likes SURPASS-2 sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.